Oral leukoplakia diagnosis and treatment in Europe and Australia: Oral Medicine Practitioners' attitudes and practice
Oral Diseases · 2023-11 · 29 (8) · 3214-3222
DOI: 10.1111/odi.14301 ↗At a glance
Journal article in Oral Diseases, published online on 2022-07-14. Written by Monica Pentenero and 4 co-authors. Institution: Department of Oncology, Oral Medicine and Oral Oncology Unit, University of Turin, Turin, Italy. Major MEDLINE topics: Leukoplakia, Oral, Precancerous Conditions. Cited 22 times so far (Crossref); 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Università degli Studi di Torino.
Abstract (original language)
The management of oral potentially malignant disorders (OPMD) including oral leukoplakia (OL) is not currently structured according to agreed guidelines. The current report presents survey data gathered from Oral Medicine Practitioners (OMPs) in Europe and Australia and is aimed to investigate attitudes and practice in the diagnosis, risk stratification and treatment of OL. In the presence of a clinical provisional diagnosis of OL, respondents reported always undertaking biopsy in 83% of cases, with most OMPs also relying on diagnostic adjuncts. The potential for malignant transformation is almost invariably assessed through epithelial dysplasia status, with other biomarkers described in the literature used less often. Active treatment of OL was considered mandatory by 20% of OMPs, while others reserve treatment for selected cases only. OMPs are mostly driven to active treatment by lesion‐related features which are frequently jointly considered including lesion site, clinical appearance and dysplasia status. Inconsistent assessment was observed regarding mild dysplasia, lesion size, presence of unavoidable trauma, exposure to tobacco and patient age. Frequently observed geographical variations were seldom statistically significant. In agreement with previous surveys, a lack of consensus around the management of OL was observed, supporting claims from learned academies and societies for treatment guidelines aiming to reduce inter‐practitioner variability.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Oncology, Oral Medicine and Oral Oncology Unit, University of Turin, Turin, Italy.
- Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy.
- Department of Stomatology University of Valencia, Hospital General Universitario de Valencia, Valencia, Spain.
- Australian Clinical Labs, Australian Centre for Oral Oncology Research & Education, Hollywood Private Hospital, Fiona Stanley Hospital, CQ University, Perth, Western Australia, Australia.
ORCID profiles: Monica Pentenero, Samuele Sutera, Giovanni Lodi, Jose V Bagan, Camile S Farah
Funding
- Università degli Studi di Torino
Cite
APA
Pentenero, M., Sutera, S., Lodi, G., Bagan, J. V., & Farah, C. S. (2023). Oral leukoplakia diagnosis and treatment in Europe and Australia: Oral Medicine Practitioners' attitudes and practice. Oral Diseases, 29(8), 3214-3222. https://doi.org/10.1111/odi.14301
Vancouver
Pentenero M, Sutera S, Lodi G, Bagan JV, Farah CS. Oral leukoplakia diagnosis and treatment in Europe and Australia: Oral Medicine Practitioners' attitudes and practice. Oral Diseases. 2023;29(8):3214-3222. doi:10.1111/odi.14301
BibTeX
@article{Pentenero2023,
author = {Pentenero, Monica and Sutera, Samuele and Lodi, Giovanni and Bagan, Jose V and Farah, Camile S},
title = {Oral leukoplakia diagnosis and treatment in Europe and Australia: Oral Medicine Practitioners' attitudes and practice},
journal = {Oral Diseases},
year = {2023},
volume = {29},
number = {8},
pages = {3214--3222},
doi = {10.1111/odi.14301}
}
EUVIMED